Akorn Inc (AKRX.O)
19 Dec 2014
|Market Cap (Mil.):||$3,980.04|
|Shares Outstanding (Mil.):||107.83|
(Updates EMC; Adds Akorn, Comcast, Grupos Salinas, Lucchini, Dentsu Aegis, Slovenske Elektrarne, Enel, BauMax, Verizon, Wind, BSkyB, Allergan, Hapag-Lloyd, Douglas, Eastman Chemical and Vodafone)
NEW YORK - U.S. specialty drugmaker Akorn Inc is exploring a bid for Belgian drugmaker UCB SA's U.S. subsidiary, a deal that would allow the company to move its tax domicile overseas in a practice known as inversion, according to people familiar with the matter.
WASHINGTON - Pharmaceutical company Akorn Inc has won U.S. antitrust approval to buy specialty prescription drug company VersaPharm Inc on condition it sell its rights to a generic tuberculosis drug, the Federal Trade Commission said on Monday.
WASHINGTON, Aug 4 - Pharmaceutical company Akorn Inc has won U.S. antitrust approval to buy specialty prescription drug company VersaPharm Inc on condition it sell its rights to a generic tuberculosis drug, the Federal Trade Commission said on Monday.
|Sun Pharmaceutical Industries Limited (SUN.NS)||Rs811.15||+7.65|
|Sun Pharmaceutical Industries Limited (SUN_p.NS)||--||--|
|Novartis AG (NOVN.VX)||CHF92.35||-1.20|
|Teva Pharmaceutical Industries Limited (TEVA.TA)||22,370.00₪||-190.00|
|Pfizer Limited (PFIZ.NS)||Rs2,037.65||+22.40|
|Allergan, Inc. (AGN.N)||$212.63||+0.45|
|Hospira, Inc. (HSP.N)||$62.44||-0.16|
|Hikma Pharmaceuticals Plc (HIK.L)||2,010.00p||+25.00|
|Sagent Pharmaceuticals Inc (SGNT.OQ)||$26.12||+1.95|
|Fresenius Kabi Oncology Ltd (FRES.M3)||--||--|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Trading Report for (AKRX). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of AKORN INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
"The Economy Matters" Report for AKRX: the economy's impact on AKRX's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.